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Abstract 
 
Background and Aims: The causes of microscopic colitis are currently poorly understood. Previous 
reports have found clinical associations with coeliac disease and genetic associations at the HLA 
locus on the ancestral 8.1 haplotype. We investigated pharmacological and genetic factors 
associated with microscopic colitis in the UK Biobank. 
Methods: 483 European UK Biobank participants were identified by ICD10 coding, and a genome-
wide association study was performed using BOLT-LMM, with a sensitivity analysis performed 
excluding potential confounders. The HLA*IMP:02 algorithm was used to estimate allele frequency 
at 11 classical human leukocyte antigen (HLA) genes, and downstream analysis was performed using 
FUMA. Genetic overlap with inflammatory bowel disease (Crohn’s disease and ulcerative colitis) was 
investigated using genetic risk scores. 
Results: We found significant phenotypic associations with smoking status, coeliac disease and the 
use of proton-pump inhibitors but not with other commonly reported pharmacological risk factors. 
Using the largest sample size to date, we confirmed a recently reported association with the MHC 
Ancestral 8.1 Haplotype. Downstream analysis suggests association with digestive tract 
morphogenesis. By calculating genetic risk scores, we also report suggestive evidence of shared 
genetic risk with Crohn’s disease, but not with ulcerative colitis. 
Conclusions: This report confirms the role of genetic determinants in the HLA in the pathogenesis of 
microscopic colitis. The genetic overlap with Crohn’s disease suggests a common underlying 
mechanism of disease. 
  
   
 
   
 
1. Introduction 
Microscopic colitis includes two related inflammatory bowel disorders, lymphocytic colitis and 
collagenous colitis that have a combined prevalence of 103 cases per 100,000 population 1. Both 
disorders cause chronic watery non-bloody diarrhoea and incontinence, and are associated with 
normal endoscopic appearances and characteristic histological features. The primary histological 
feature of lymphocytic colitis is patchy lymphocytic infiltration of the epithelium with preserved 
crypt architecture. Collagenous colitis is characterised by the presence of a thickened subepithelial 
collagen layer. 
The pathogenesis of microscopic colitis is poorly elucidated: it reportedly involves immune 
responses to luminal factors in genetically predisposed individuals 2. A recent association study 
based on Immunochip data reported association between HLA alleles on the 8.1 haplotype and 
collagenous colitis 3 but not with lymphocytic colitis 4 in cohorts comprising 314 patients with 
collagenous colitis, 122 patients with lymphocytic colitis and 4,299 controls. Further, Westerlind et. 
al. reports genetic overlap with inflammatory bowel disease (IBD) by comparing the number of 
nominally significant Single Nucleotide Polymorphisms (SNPs) in both phenotypes 3. The most 
frequently cited environmental risk factors are medications, with non-steroidal anti-inflammatory 
drugs (NSAIDs), proton-pump inhibitors (PPIs) and selective serotonin reuptake inhibitors (SSRIs) 
most commonly implicated 5–7. There have been no reported investigations of potential 
pharmacogenetic risk factors for microscopic colitis. 
We sought phenotypic and genetic associations with microscopic colitis in individuals of European 
ancestry enrolled in the UK Biobank, and report subsequent downstream analysis. Subsequently, we 
stratified the data by drug use and performed a GWAS to identify pharmacogenetic associations. 
Finally, we calculated genetic risk scores for IBD (Inflammatory Bowel Disease) to quantify in detail 
genetic overlap with microscopic colitis. 
2. Methods 
2.1 Participants 
The UK Biobank is a population-based prospective study comprising more than 500,000 UK 
participants aged 40-69 years at time of recruitment between 2006 and 2010. Participants are 
actively followed, and phenotype data collected includes demographics, medical conditions, 
medications, lifestyle and anthropometric measurements. SNP genotypes were generated from the 
Affymetrix Axiom UK Biobank array (∼450,000 individuals) and the UK BiLEVE array (∼50,000 
individuals). More detail on the UK Biobank can be found elsewhere 8.  
We defined microscopic colitis by the ICD10 code K52.8. The full UK Biobank dataset contains 522 
K52.8 cases and 502,097 controls (104.0/100,000 persons). We stratified the data to contain only 
white Europeans by performing principal component analysis in the 1000 Genomes reference panel. 
Of the 451,099 participants remaining, 483 are cases and 450,616 are controls (107.2/100,000 
persons). Of the 483 cases, 335 (69.4%) had K52.8 as their primary diagnosis code. 
We investigated pharmacological associations with NSAIDs, PPIs and SSRIs using the medication 
codes reported in the UK Biobank (Data-Field 20003: Treatment/medication code). Drugs included 
and their relative frequencies in the UK Biobank among cases and controls can be found in 
supplementary table 1.  
   
 
   
 
2.2 Statistical Methods 
We performed tests for association with clinical characteristics using the Mann Whitney U test for 
continuous data and Fisher’s exact test for categorical data. P values are reported uncorrected for 
multiple testing, but we used an adjusted p-value threshold of 0.0045 for statistical significance for 
the clinical data. 
Quality control of the genotype data was performed centrally by the UK Biobank.9 For the genome-
wide association study, we used ~12.0M Haplotype Reference Consortium (HRC) imputed variants 
with an imputation r2 ≥ 0.9, minor allele frequency (MAF) ≥ 0.025 (2.5%) and with a Hardy–Weinberg 
equilibrium p>1×10-12. Further, individuals with IBD or coeliac disease were excluded from all genetic 
analyses, leaving 423 cases and 445,232 controls. 
We performed our main association test using BOLT-LMM v2.3 10, which applies a linear mixed 
model (LMM) to adjust for the effects of population structure and individual relatedness and 
allowed us to include all related individuals in our white European subset, rather than reducing the 
sample size to only include the unrelated individuals (379,768). Covariates included were age, sex, 
recruiting centre and genotyping chip. A more detailed explanation of GWAS methodology can be 
found in our recent publication 11, and a principal components plot is available in Supplementary 
Figure 1. Odds Ratios from BOLT-LMM were calculated by 𝑂𝑅 = 𝑒𝛽 / (𝜇 ∗ (1 − 𝜇)) where 𝜇 = case 
fraction, and standard errors divided by (𝜇 ∗  (1 −  𝜇)) to give confidence intervals. Following the 
GWAS, FUMA’s SNP2GENE analysis was used to convert SNP data into genomic loci, and perform a 
gene-set enrichment analysis using MAGMA 12. 
As a sensitivity analysis we also performed a secondary GWAS on a more refined phenotype using 
only white British unrelated individuals, in which we excluded coeliac and inflammatory bowel 
disease (IBD) participants (defined by ICD10, ICD9 and Self Report) and participants using PPIs . 
Controls were further refined by excluding those with a diagnosis (self-reported or in HES data) 
before the age of 70 of coronary heart disease, stroke, diabetes, chronic obstructive pulmonary 
disease, renal failure, any cancer (excluding non-melanoma skin cancer), and those who had died 
from any cause before the age of 70. To further limit the possibility of type 1 errors, this GWAS was 
performed using Fisher’s exact test. This analysis used 335 cases and 64,300 controls (253 cases and 
49,608 controls following filtering related individuals). 
Imputation of HLA alleles was performed using the HLA*IMP:02 algorithm to estimate allele 
frequency at 11 classical human leukocyte antigen (HLA) genes: HLA-A, -B, -C, -DRB5, -DRB4, -DRB3, -
DRB1, -DQB1, -DQA1, -DPB1 and -DPA1 using reference panels described by Motyer et al 13. This 
procedure provides accurate dosages for 362 SNPs in the HLA region, allowing identification of 
genetic basis of autoimmune processes with greater precision14. 
Genetic risk scores for ulcerative Colitis (UC), Crohn’s disease (CD) and IBD were calculated using 
odds ratios for previously published SNPs 15. From that study, using only SNPs that were genome-
wide significant at 5×10-8 and also present in our imputation panel, we have 145 SNPs for CD, 89 for 
UC and 162 for IBD. To quantify genetic overlap, for each IBD phenotype, we compared the mean 
GRS among the microscopic colitis patients with controls (defined as not having UC, CD, IBD or 
microscopic colitis). A GRS containing 𝑁 SNPs was calculated according to the equation below where 
𝛽 is the 𝛽-coefficient (log odds ratio) representing the association between each SNP and the 
relevant phenotype and 𝑑𝑖  is the estimated dosage. Statistical associations are quantified using a 2-
tailed t-test. 
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3. Results 
3.1 Clinical Associations 
Variable Cases Controls p-value 
Age at recruitment (years) 61.9 [56.2 – 65.4] 58.6 [50.5 – 63.8] 5×10-15 
Body mass index 26.6 [23.7 – 29.6] 26.7 [24.1 – 29.9] 0.195 
Townsend Deprivation Index -2.03 [-3.55 – 0.28] -2.27 [-3.70 – 0.23] 0.171 
Female 65.6% [317/483] 54.2% [244,531/450,616] 5×10-7 
Current smoker 14.7% [71/483] 10.4% [46,792/450,616] 0.003 
Coeliac disease 3.3% [16/483] 0.4% [1,991/450,616] 7×10-10 
IBD 9.5% [46/483] 0.8% [3,896/450,616] 2×10-32 
Using PPIs 20.3% [98/483]  10.3% [46,397/450,616] 9×10-11 
Using SSRIs 5.8% [28/483] 4.0% [18,003/450,616] 0.048 
Using NSAIDs 28.4% [137/483] 26.3% [118,687/450,616] 0.326 
Using Statins 19.7% [388/483] 16.3% [73,365/450,616] 0.048 
Table 1: Clinical Associations with Microscopic Colitis – Table showing demographic and drug use associations in the UK 
Biobank. Continuous variables are reported in terms of median [interquartile range]. All p values were computed by a 
Fisher’s or Mann-Whitney U test. p value threshold was 0.0045 after Bonferroni correction. Significant associations are in 
bold. 
Demographic and drug associations are shown in Table 1. Microscopic colitis patients were more 
likely to be older, female and to be a current smoker. We find white European UK Biobank 
participants with microscopic colitis had an 8 times higher risk of coeliac disease and 12 times higher 
risk of IBD than controls. We found no evidence of association with body mass index (BMI), or 
socioeconomic status (defined by Townsend Deprivation Index). 
In terms of drug associations, patients with microscopic colitis were 2-times more likely to be using 
PPIs (a sub-analysis suggests 1.95 for omeprazole, 2 times for lansoprazole). We found no significant 
associations for SSRIS, NSAIDs or statins when accounting for multiple testing. We also performed a 
sub-analysis of NSAIDs, stratifying by COX1 and COX2 inhibitors, but found no significant 
associations. All clinical associations were robust to adjustment for age and sex in a multivariable 
logistic regression model, and testing with or without the related individuals. 
   
 
   
 
3.2 GWAS Results 
 
 
Figure 1: Manhattan Plot – A plot showing the –log10(p) values for each SNP in the HRC Imputation Panel with p<0.01, 
computed using Bolt-LMM and plotted using an in-house MATLAB script which we have made publicly available on the 
MATLAB File Exchange 16. The horizontal dashed line is the genome wide significance threshold at p=5×10-8. The strongly 
significant signal on Chromosome 6 lies in the HLA region, with lead SNP rs2596560, p=3×10-8.  
Figure 1 shows a Manhattan plot of all SNPs that passed QC and had p<0.01. We find a strong 
association for microscopic colitis on chromosome 6, in the HLA region, with lead SNP rs2596560 
(OR 0.64, 95% confidence interval 0.56-0.72, p=3×10-8, MAF 0.24 vs 0.33).  The odds ratio remained 
the same at the lead SNP (OR 0.64, 95% confidence interval 0.53-0.77, p=3.3×10-6) when we 
performed our secondary analysis, on the refined phenotype using Fisher’s exact test  
Summary statistics for all genomic risk loci with p<10-5 are available in Supplementary Table 2, and 
the full GWAS summary statistics can be found at https://www.ebi.ac.uk/gwas/home. In 
Supplementary Figure 2 we present a QQ plot. The genomics inflation factor λ was 1.0000. We also 
include the top 10 results of a MAGMA Gene-set Analysis in Supplementary Table 3, in which we find 
a Bonferroni-significant association for digestive tract morphogenesis.  
 
SNP Allele Frequency Beta Standard Error p-value 
B_801 0.143 4.3 × 10-4 9.4 × 10-5 3.9 × 10-6 
DRB1_301 0.147 3.7 × 10-4 9.2 × 10-5 5.6 × 10-5 
DRB3_9901 0.655 -2.6 × 10-4 6.9 × 10-5 1.5 × 10-4 
DRB3_101 0.166 3.3 × 10-4 8.8 × 10-5 2.0 × 10-4 
DQA1_501 0.230 2.9 × 10-4 7.8 × 10-5 2.1 × 10-4 
C_701 0.175 3.2 × 10-4 8.6 × 10-5 2.4 × 10-4 
DQB1_201 0.148 3.4 × 10-4 9.2 × 10-5 2.7 × 10-4 
Table 2: Classical HLA Alleles - A table showing the allele frequencies, beta, standard error and p values of all classical HLA 
alleles with a p value below 5×10-4 (computed through Bolt-LMM) and MAF >0.01. SNPs in bold are part of the HLA A1-B8-
DR3-DQ2 (ancestral MHC 8.1) haplotype. 
HLA imputation demonstrated that the SNP rs2596560 associates with the class I and II alleles that 
comprise the ancestral MHC 8.1 haplotype previously been linked with microscopic colitis, with lead 
   
 
   
 
SNP B_0801 passing genome-wide significance. Results from BOLT -LMM runs on the HLA imputed 
alleles are given in Table 2, with alleles on the MHC 8.1 haplotype highlighted in bold. 
To follow up on the phenotypic association with PPIs, we sought pharmacogenetic associations by 
using PPIs as an inclusion criterion (comparing PPIs with microscopic colitis and PPIs with no 
microscopic colitis). However, there were no genome-wide significant associations for this GWAS.  
3.3 Genetic Overlap with IBD 
Table 3 shows the mean Crohn’s disease, ulcerative colitis and IBD genetic risk scores and 95% 
confidence intervals for microscopic colitis patients and controls. 
 
Disease for which 
genetic risk score 
derived 
Mean (95% CI) score for 
microscopic colitis patients 
Mean (95% CI) score for 
controls 
p value 
Crohn’s Disease 0.9688 (0.9632-0.9739) 0.9634 (0.9632-0.9636) 0.035 
Ulcerative Colitis 0.9928 (0.9859-0.9997) 0.9890 (0.9888-0.9892) 0.261 
IBD 0.9286 (0.9237-0.9335) 0.9230 (0.9229-0.9231) 0.019 
Table 3: Genetic Risk Score Means and Associations - Microscopic colitis patients are significantly enriched for genetic risk 
factors for Crohn’s disease and IBD, but not for ulcerative colitis 
Microscopic colitis patients had a higher genetic risk for all three tests, but only Crohn’s disease 
(p=0.035) and IBD (p=0.019) were significant at the 5% confidence level, suggesting some shared 
genetic pathway behind microscopic colitis and Crohn’s disease / IBD. These were robust to applying 
the same tests on only the unrelated individuals in the UK biobank as a sensitivity analysis. In Table 4 
we show which of the known risk loci replicate at p<0.05 for microscopic colitis, although none of 
these are significant when Bonferonni correcting the p value threshold. 
 
GRS Chr Pos A1 A1 Freq Beta SE P 
Both 10 6081230 C 0.836092 2.2 × 10-4 8.85 × 10-5 1.4 × 10-2 
Both 2 28614794 C 0.519615 1.5 × 10-4 6.58 × 10-5 1.9 × 10-2 
Both 22 30493882 G 0.55509 1.8 × 10-4 6.58 × 10-5 7.7 × 10-3 
Both 17 32593665 A 0.72546 1.6 × 10-4 7.32 × 10-5 3.0 × 10-2 
Both 21 45615741 G 0.394392 1.3 × 10-4 6.69 × 10-5 4.7 × 10-2 
Both 7 50175654 G 0.573233 -1.7 × 10-4 6.62 × 10-5 1.2 × 10-2 
Both 7 50304461 C 0.33364 -1.4 × 10-4 6.94 × 10-5 4.1 × 10-2 
Crohn's Disease 12 6491125 G 0.646309 -1.6 × 10-4 6.93 × 10-5 1.8 × 10-2 
IBD 7 2869985 T 0.697662 2.3 × 10-4 7.12 × 10-5 1.1 × 10-3 
IBD 13 27531267 T 0.82362 2.2 × 10-4 8.58 × 10-5 1.1 × 10-2 
Table 4: Nominally Significant SNPs in Crohn’s Disease and IBD GRS – Summary statistics of the known risk variants for 
Crohn’s disease and IBD in our microscopic colitis GWAS for those that pass the nominal p value threshold of 0.05. 
4. Discussion 
We have conducted a clinical and genetic case-control study of microscopic colitis in the UK Biobank. 
We confirm previously reported phenotypic associations with age, sex, coeliac disease, smoking 
status and PPIs. In a genome-wide association study, we have confirmed recent reports of 
association with SNPs on the MHC 8.1 haplotype, indicating an immune component to the 
   
 
   
 
pathogenesis of microscopic colitis. Using genetic risk scores, we obtain results consistent with 
overlap in genetic risk factors for Crohn’s disease and IBD but not ulcerative colitis. This may suggest 
shared genetic pathways between these phenotypes. 
This is the largest genome-wide association study of microscopic colitis to date, and the first to look 
at genetic overlap between microscopic colitis and IBD by using a genetic risk score. The main 
limitation of the study is that the ICD10 coding in the UK Biobank only covers the first decimal place: 
K52.8. We acknowledge two limitations as a consequence: this code also includes eosinophilic 
gastritis and colitis, and that we are unable to distinguish lymphocytic from collagenous colitis. 
However, eosinophilic gastritis and colitis are of very low prevalence (5.1 and 2.1 /100,000 persons 
respectively)18 compared to microscopic colitis (103.0/100,000 persons)1.  
The UK biobank ICD10 data relies on hospital coding data, which has limitations in terms of whether 
patients have had a coded diagnosis at hospital and relies on the accuracy of hospital coding; 
however, their use is standard practice in literature performing UK Biobank GWASs. This study was 
only performed using white Europeans, and further studies are required to determine if results are 
consistent across other ethnic groups. The UK Biobank also only includes patients between the ages 
of 40 and 69 at recruitment, although this covers the peak age of onset for microscopic colitis. We 
are confident our main GWAS result is not a false positive due to the high MAF of the lead SNP and 
aligning closely with previous work, but we acknowledge that due to having under 500 cases, there 
may by many SNPs we were unable to detect due to low odds ratio or MAF. A meta-analysis 
combining the results of this study and others may help identify further associations. 
To follow up on the strong association with PPIs, we performed a GWAS to find possible underlying 
pharmacogenetic associations, but there were no genome-wide significant SNPs. A follow-up study 
with a dedicated drug-exposed cohort would have greater power to detect such associations, as has 
been demonstrated in our recent study of thiopurine-induced myelosuppression19.  
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Supplementary Table 1 
 
Class Drug Biobank Code Cases Controls 
PPIs Omeprazole  1140865634 11.2% [54/483] 6.4% [28,868/450,616] 
Lansoprazole 1140864752 7.7% [37/483] 3.8% [17,065/450,616] 
Esomeprazole 1141177526 1% [5/483] 0.35% [1,590/450,616] 
Rabeprazole 1141168584 0.4% [2/483] 0.2% [842/450,616] 
Pantoprazole 1140929012 1% [5/483] 0.2% [854/450,616] 
SSRIs Sertraline  1140867878 0.6% [3/483] 0.5% [2,121/450,616] 
Paroxetine 1140867888 0.8% [4/483] 0.3% [1,539/450,616] 
Fluvoxamine 1140879544 0% [0/483] 0.01% [29/450,616] 
Fluoxetine 1140879540 1.9% [9/483] 1.2% [5,436/450,616] 
Escitalopram 1141180212 0.4% [2/483] 0.2% [825/450,616] 
Citalopram 1140921600 2.1% [10/483] 1.8% [8,187/450,616] 
NSAIDs Aceclofenac 1140925806 0% [0/483] 0.01% [54/450,616] 
Aspirin 1140868226 18.4 [89/483] 13.7 [61,826/450,616] 
Celecoxib 1141176662 0.2% [1/483] 0.1% [492/450,616] 
Dexketoprofen 1141164746 0% [0/483] 0% [7/450,616] 
Diclofenac Sodium 1140878036 0% [0/483] 0.07% [307/450,616] 
Etodolac 1140871188 0% [0/483] 0.07% [335/450,616] 
Etoricoxib 1141180140 0% [0/483] 0.09 [407/450,616] 
Fenoprofen 1140871226 0% [0/483] 0% [3/450,616] 
Ibuprofen 1140871310 11% [53/483] 13% [58,536/450,616] 
Ketoprofen 1140871506 0% [0/483] 0.03% [135/450,616] 
Mefenamic Acid 1140871542 0% [0/483] 0.1% [476/450,616] 
Meloxicam 1140926732 0.6% [3/483] 0.3% [1,310/450,616] 
Nabumetone 1140875336 0% [0/483] 0.05% [206/450,616] 
Naproxen 1140871462 0.6% [3/483] 0.74% [3,353/450,616] 
Piroxicam 1140871666 0.2% [1/483] 0.04% [158/450,616] 
Sulindac 1140871604 0% [0/483] 0% [15/450,616] 
Tenoxicam 1140875346 0% [0/483] 0% [13/450,616] 
Tiaprofenic Acid 1140871614 0% [0/483] 0% [8/450,616] 
Statins atorvastatin  1141146234 3.1% [15/483] 3.4% [15,439/450,616] 
fluvastatin 1140888594 0.2% [1/483] 0.05% [213/450,616] 
pravastatin  1140888648 0.4% [2/483] 0.6% [2457/450,616] 
rosuvastatin  1141192410 0.8% [4/483] 0.7% [29,44/450,616] 
simvastatin  1140861958 15.3% [74/483] 11.9% [53,451/450,616] 
Supplementary Table 1: UK Biobank Medication Codes – The treatment codes in UK Biobank used to 
define drug phenotypes. 
 
  
   
 
   
 
Supplementary Table 2 
 
 
CHR POS A1 A1FREQ BETA SE P 
1 102300829 A 0.78544 -0.00039 7.98E-05 1.20E-06 
1 211852006 C 0.895625 0.000483 0.000107 6.80E-06 
2 29002900 A 0.96978 -0.00088 0.000192 4.50E-06 
2 44211546 A 0.420328 -0.00031 6.65E-05 3.90E-06 
3 21580556 T 0.972868 -0.0009 0.000201 7.60E-06 
4 24338324 C 0.774897 -0.00038 7.85E-05 1.40E-06 
4 108478191 T 0.831665 0.000448 8.72E-05 2.80E-07 
5 6222490 C 0.973156 -0.00093 0.000203 4.60E-06 
5 24256226 C 0.943636 -0.00066 0.000143 3.60E-06 
6 31355318 T 0.758228 -0.00042 7.64E-05 3.30E-08 
6 65350792 G 0.83685 0.000415 8.86E-05 2.80E-06 
6 104003704 C 0.929096 -0.00057 0.000128 8.20E-06 
6 106000790 C 0.951844 -0.00082 0.000153 8.90E-08 
7 25573204 G 0.789508 -0.00039 8.04E-05 1.20E-06 
7 47391321 G 0.970032 -0.00092 0.000191 1.60E-06 
8 12517525 G 0.969694 -0.00097 0.000192 4.50E-07 
11 11931183 C 0.950888 -0.00071 0.000152 2.50E-06 
11 105858586 A 0.911153 -0.00055 0.000117 2.40E-06 
13 54703907 GCA 0.974328 -0.00107 0.00021 3.30E-07 
14 41804188 A 0.520016 -0.0003 6.55E-05 5.90E-06 
15 64768700 T 0.972247 -0.00102 0.000199 3.10E-07 
16 26117039 C 0.871776 -0.00048 9.80E-05 1.20E-06 
17 6571439 C 0.964387 -0.00088 0.000176 5.80E-07 
20 2374455 G 0.869848 -0.00046 9.80E-05 2.50E-06 
 
Supplementary Table 2: GWAS Summary Statistics – All risk loci with p<10-5 from the main GWAS, 
using all European Biobank Participants and BOLT-LMM. N=483 cases and 450,616 controls. SNPs 
have been condensed into genomic loci using FUMA 12. Full summary statistics can be found at the 
GWAS catalog at https://www.ebi.ac.uk/gwas/home. 
   
 
   
 
Supplementary Table 3 
 
 
Gene Set N genes Beta Beta STD SE P Pbon 
GO bp:go digestive tract 
morphogenesis 
48 0.601 0.0303 0.133 3.02E-06 0.032 
GO bp:go morphogenesis of an 
epithelial fold 
15 0.802 0.0226 0.212 7.50E-05 0.799 
GO bp:go negative regulation of bmp 
signaling pathway 
41 0.493 0.023 0.135 0.000127 1 
GO bp:go regulation of calcium ion 
transmembrane transport 
116 0.279 0.0218 0.0769 0.000146 1 
GO bp:go prostate gland development 42 0.471 0.0222 0.135 0.000243 1 
GO bp:go wnt signaling pathway 
calcium modulating pathway 
39 0.464 0.0211 0.133 0.000245 1 
GO mf:go r smad binding 23 0.62 0.0216 0.179 0.000274 1 
GO bp:go regulation of calcium ion 
transmembrane transporter activity 
71 0.33 0.0202 0.0957 0.000283 1 
GO bp:go pattern specification 
process 
416 0.148 0.0217 0.0431 0.000304 1 
Supplementary Table 3: MAGMA Gene-Set Analysis – Top 10 results of a gene set enrichment 
analysis performed FUMA. We find a significant association for digestive tract morphogenesis when 
accounting for multiple testing. 
 
 
  
   
 
   
 
Supplementary Figure 1 
 
 
Derived European set of individuals after K-means clustering, anchoring on centres of PCs 1-4 for 
individuals self-reporting as from European population 
  
   
 
   
 
Supplementary Figure 2
 
A QQ plot of our main GWAS result using BOLT-LMM on a Biobank Cohort with IBD and coeliac 
patients excluded. The median p value was 0.5000 and inflation factor λ=1.0000, showing no 
statistical inflation of p values. 
